Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. Class A

Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. Class A

SSZSE:301234
103.88
CNY
+1.78
(+1.74%)
0.26EPS
514.85P/E
9.22BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.99
8.51
9.57
9.22
10.06
9.2
7.85
7.02
6.74
6.07
Basic EPS, GAAP
0.42
0.66
1.04
1.11
1.34
1.19
0.89
0.59
0.28
0.26
Free Cash Flow per Basic Share
0.46
-0.17
1.27
0.42
0.12
-0.88
0.16
0.76
0.79
- -
Dividend per Share
0.42
0.24
0.26
0.71
0.02
0.01
0.5
0.4
0.3
- -
Book Value per Share
1.82
2.48
2.7
3.81
5.15
10.64
11.03
11.21
11.19
11.25
Tangible Book Value per Share
1.67
2.34
2.56
3.68
4.99
10.52
10.92
11.12
11.09
11.16
Basic Weighted Avg Shares
52
51
51
51
51
60
68
68
68
68
Sales/Revenue/Turnover
360
436
487
471
513
547
534
477
458
413
Operating Margin (%)
11.99
10.5
14.23
14.9
16.73
12.71
12.14
8.47
4.07
5.68
Depreciation Expense
10
11
12
14
18
23
31
39
39
- -
Net Income, GAAP
22
34
53
57
68
71
60
40
19
18
Effective Tax Rate (%)
27.42
18.61
17.53
17.28
14.34
3.43
15.05
13.96
17.47
11.69
Profit Margin (%)
6.01
7.75
10.86
12.04
13.33
12.96
11.29
8.37
4.12
4.34
Working Capital
1
26
25
67
95
422
419
455
482
482
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
93
127
138
194
263
723
750
762
761
765
Return on Invested Capital (%)
- -
25.45
39.63
34.03
28.69
12.13
7.99
5.42
2.57
2.42
Return on Capital (%)
- -
29.46
37.05
30.68
27.92
14.31
8.18
5.28
2.48
2.36
Return on Common Equity (%)
- -
30.76
40.02
34.18
29.92
14.38
8.18
5.29
2.48
2.36

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
2,527
2,237
9,224

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
555
558
567
Cash, Cash Equivalents & STI
407
413
414
Accounts Receivable, Net
85
79
69
Inventories
42
46
61
Total Current Liabilities
69
77
85
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
43.13%
-0.19%
Free Cash Flow
- -
-155.68%
3.29%
Net Income, GAAP
- -
-15.44%
-52.73%
Sales/Revenue/Turnover
- -
-0.3%
-4.01%
Total Cash Common Dividend
- -
1,039.54%
-25.05%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
122
130
135
477
2025
104
113
- -
113
458
2026
101
102
97
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
0.17
0.18
0.08
0.59
2025
0.08
0.07
- -
0.01
0.28
2026
0.12
0.11
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.03
- -
0.4
2025
- -
- -
- -
- -
0.3
2026
- -
- -
- -
- -
- -

Company Description

CEO
Hong Yu Zhang
Full Time Employees
856
Sector
Health technology
Industry
Medical specialties
Address
Anqing China
IPO Date
Jul 5, 2022
Business
Anhui Hongyu Wuzhou Medical Manufacturer Co., Ltd. is a China-based medical device company primarily engaged in the research, development, manufacturing, and global distribution of single-use sterile medical consumables and clinical injection supplies. Founded in 2011 and headquartered in Anqing, Anhui Province, China, the company is publicly listed on the ChiNext board of the Shenzhen Stock Exchange under the ticker symbol 301234. The company operates across multiple dedicated product lines within the medical consumables sector, providing specialized product offerings: infusion and transfusion administration devices, including gravity infusion sets, precision filter infusion sets, blood transfusion sets, and scalp vein sets; injection and puncture equipment, encompassing conventional disposable sterile syringes, safety auto-disable syringes, insulin syringes, insulin pen needles, hypodermic needles, blood collection needles, and intravenous cannulas; and supplementary clinical diagnostic and protective consumables, including electronic sphygmomanometers, medical protective masks, surgical dressings, and catheter accessories. In addition to marketing proprietary branded products, the company delivers contract manufacturing, original equipment manufacturing, and original design manufacturing services to international medical equipment and pharmaceutical partners, operating under global regulatory standards including ISO 13485 quality management certification, European CE conformity, and United States FDA 510(k) product clearances. The company caters to institutional healthcare clients, including general and specialized hospitals, clinical laboratories, blood centers, ambulatory surgical facilities, and multinational healthcare supply distributors. Geographically, while maintaining substantial market penetration across mainland China, the company derives a significant portion of its revenues from international markets, exporting products to more than 80 countries and regions across Europe, North America, South America, Asia, and Africa. In recent corporate developments, the company announced a significant strategic asset acquisition to purchase 100% equity in Xuanzhi Electronic Technology (Shanghai) Co., Ltd. through a combined structure of share issuance and cash payment, accompanied by supporting capital fundraising to accelerate technological capabilities and business diversification. Concurrently, the company has expanded its advanced automated manufacturing lines in Anhui, accelerated the commercialization of high-value safety-engineered needle and pre-filled injection systems, and broadened international trade partnerships to navigate evolving global regulatory requirements and enhance its supply chain scale across overseas markets.